Uterine fibroids are the most common gynecologic tumors with a significant medical and financial burden. Several genetic, hormonal, and biological factors have been shown to contribute to the development and growth of fibroid tumors. Of these factors, estrogen is particularly critical since fibroids are considered estrogen dependent because no prepubertal cases have been described in the literature and tumors tend to regress after menopause. Understanding the role of estrogen in fibroids is not only important for understanding the pathobiology of fibroids but also for the development of successful therapeutics. In this review, we discuss the types and structure of estrogen receptors (nuclear and membrane bound, including α and β receptors and G protein-coupled estrogen receptor 1 GPER1). Estrogen-signaling pathways in fibroids include genomic (direct and indirect) and nongenomic including Ras-Raf-MEK (MAPK/Erk Kinase)-mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinase (PI3K)-phosphatidylinositol-3,4,5-trisphosphate (PIP3)-Akt (Protein kinase B)-mammalian target of rapamycin (mTOR) pathways; shortly Ras-Raf-MEK-MAPK and PI3K-PIP3-Akt-mTOR pathways. Several aberrations in estrogen receptors and signaling pathways are implicated in fibroid pathobiology. Current therapeutic and research agents targeting ERs/signaling include gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists, aromatase inhibitors, selective ER modulators, gene therapy, and others. Future research can identify potential targets for the development of novel treatments. In particular, epigenomics of estrogen activity and individualized (precision) medicine appear to be attractive areas for future research.
TownsendDESparkesRSBaludaMCMcClellandG. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis by glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol. 1970;107(8):1168–1173.
2.
PandisNHeimSBardiG. Chromosome analysis of 96 uterine leiomyomas. Cancer Genet Cytogenet. 1991;55(1):11–18.
3.
BulunSE. Uterine fibroids. N Engl J Med. 2013;369(14):1344–1355.
4.
OkoloS. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):571–588.
5.
MehineMKaasinenEMakinenN. Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med. 2013;369(1):43–53.
6.
TalRSegarsJH. The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy. Hum Reprod Update. 2014;20(2):194–216.
7.
KhanKNKitajimaMHirakiK. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod. 2010;25(3):642–653.
8.
LethabyAVollenhovenBSowterM. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001(2):CD000547.
9.
MoherDLiberatiATetzlaffJAltmanDGGroupP. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
10.
RazandiMPedramAGreeneGLLevinER. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol. 1999;13(2):307–319.
11.
EllmannSStichtHThielFBeckmannMWStrickRStrisselPL. Estrogen and progesterone receptors: from molecular structures to clinical targets. Cell Mol Life Sci. 2009;66(15):2405–2426.
12.
AscenziPBocediAMarinoM. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med. 2006;27(4):299–402.
13.
KumarRZakharovMNKhanSH. The dynamic structure of the estrogen receptor. J Amino Acids. 2011;2011:812540.
14.
BorahayMAAl-HendyAKilicGSBoehningD. Signaling pathways in leiomyoma: understanding pathobiology and implications for therapy. Mol Med. 2015;21:242–256.
15.
MenasceLPWhiteGRHarrisonCJBoyleJM. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics. 1993;17(1):263–265.
16.
EnmarkEPelto-HuikkoMGrandienK. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997;82(12):4258–4265.
17.
KuiperGGCarlssonBGrandienK. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138(3):863–870.
18.
DecheringKBoersmaCMosselmanS. Estrogen receptors alpha and beta: two receptors of a kind?Curr Med Chem. 2000;7(5):561–576.
19.
GrachevskyNO. Signal Transduction Research Trends. New York, NY: Nova Science Publishers; 2007.
20.
MatthewsJGustafssonJA. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv. 2003;3(5):281–292.
21.
PedramARazandiMLevinER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol. 2006;20(9):1996–2009.
ChamblissKLYuhannaISAndersonRGMendelsohnMEShaulPW. ERbeta has nongenomic action in caveolae. Mol Endocrinol. 2002;16(5):938–946.
24.
PedramARazandiMDeschenesRJLevinER. DHHC-7 and -21 are palmitoylacyltransferases for sex steroid receptors. Mol Biol Cell. 2012;23(1):188–199.
25.
ThomasPPangYFilardoEJDongJ. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 2005;146(2):624–632.
SoltysikKCzekajP. Membrane estrogen receptors—is it an alternative way of estrogen action?J Physiol Pharmacol. 2013;64(2):129–142.
28.
ProssnitzERArterburnJBSmithHOOpreaTISklarLAHathawayHJ. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol. 2008;70:165–190.
VrtacnikPOstanekBMencej-BedracSMarcJ. The many faces of estrogen signaling. Biochem Med (Zagreb). 2014;24(3):329–342.
31.
LodishHF. Molecular Cell Biology. 6th ed. New York, NY: W. H. Freeman; 2008.
32.
KnoblauchRGarabedianMJ. Role for Hsp90-associated cochaperone p23 in estrogen receptor signal transduction. Mol Cell Biol. 1999;19(5):3748–3759.
33.
PrattWBToftDO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood). 2003;228(2):111–133.
34.
KlingeCMJerniganSCMattinglyKARisingerKEZhangJ. Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors. J Mol Endocrinol. 2004;33(2):387–410.
35.
O’LoneRFrithMCKarlssonEKHansenU. Genomic targets of nuclear estrogen receptors. Mol Endocrinol. 2004;18(8):1859–1875.
36.
BjornstromLSjobergM. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol. 2005;19(4):833–842.
MonjePHernandez-LosaJLyonsRJCastelloneMDGutkindJS. Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. J Biol Chem. 2005;280(42):35081–35084.
39.
WeinbergRA. The Biology of Cancer. New York, NY: Garland Science; 2007.
40.
CantleyLC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655–1657.
41.
HeYYCaiBYangYXLiuXLWanXP. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci. 2009;100(6):1051–1061.
42.
FilardoEJThomasP. Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology. Endocrinology. 2012;153(7):2953–2962.
43.
PrenzelNZwickEDaubH. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 1999;402(6764):884–888.
44.
DonnezJVazquezFTomaszewskiJ. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101(6):1565–1573.e1561-e1518.
SumitaniHShozuMSegawaT. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology. 2000;141(10):3852–3861.
47.
CookJDWalkerCL. Treatment strategies for uterine leiomyoma: the role of hormonal modulation. Semin Reprod Med. 2004;22(2):105–111.
48.
BulunSESimpsonERWordRA. Expression of the CYP19 gene and its product aromatase cytochrome P450 in human uterine leiomyoma tissues and cells in culture. J Clin Endocrinol Metab. 1994;78(3):736–743.
49.
BulunSEImirGUtsunomiyaH. Aromatase in endometriosis and uterine leiomyomata. J Steroid Biochem Mol Biol. 2005;95(1-5):57–62.
50.
KasaiTShozuMMurakamiK. Increased expression of type I 17beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol in uterine leiomyoma. J Clin Endocrinol Metab. 2004;89(11):5661–5668.
51.
DuhanNMadaanSSenJ. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2013;171(2):329–332.
52.
MarshEEBulunSE. Steroid hormones and leiomyomas. Obstet Gynecol Clin North Am. 2006;33(1):59–67.
53.
IshikawaHIshiKSernaVAKakazuRBulunSEKuritaT. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010;151(6):2433–2442.
54.
IshikawaHReierstadSDemuraM. High aromatase expression in uterine leiomyoma tissues of African-American women. J Clin Endocrinol Metab. 2009;94(5):1752–1756.
55.
BenassayagCLeroyMJRigourdV. Estrogen receptors (ERalpha/ERbeta) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma. Am J Physiol. 1999;276(6 pt 1): E1112–E1118.
56.
TianRWangZShiZ. Differential expression of G-protein-coupled estrogen receptor-30 in human myometrial and uterine leiomyoma smooth muscle. Fertil Steril. 2013;99(1):256–263.
57.
HermonTLMooreABYuLKisslingGECastoraFJDixonD. Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium. Virchows Arch. 2008;453(6):557–569.
58.
SwartzCDAfshariCAYuLHallKEDixonD. Estrogen-induced changes in IGF-I, Myb family and MAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines. Mol Hum Reprod. 2005;11(6):441–450.
59.
AndersenJGrineEEngCL. Expression of connexin-43 in human myometrium and leiomyoma. Am J Obstet Gynecol. 1993;169(5):1266–1276.
60.
GustavssonIEnglundKFaxenMSjoblomPLindblomBBlanckA. Tissue differences but limited sex steroid responsiveness of c-fos and c-jun in human fibroids and myometrium. Mol Hum Reprod. 2000;6(1):55–59.
61.
DimitrovaIKRicherJKRudolphMC. Gene expression profiling of multiple leiomyomata uteri and matched normal tissue from a single patient. Fertil Steril. 2009;91(6):2650–2663.
62.
BarbarisiAPetilloODi LietoA. 17-Beta estradiol elicits an autocrine leiomyoma cell proliferation: evidence for a stimulation of protein kinase-dependent pathway. J Cell Physiol. 2001;186(3):414–424.
63.
MatsuoHKurachiOShimomuraYSamotoTMaruoT. Molecular bases for the actions of ovarian sex steroids in the regulation of proliferation and apoptosis of human uterine leiomyoma. Oncology. 1999;57(suppl 2):49–58.
64.
ShimomuraYMatsuoHSamotoTMaruoT. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab. 1998;83(6):2192–2198.
65.
GaoZMatsuoHNakagoSKurachiOMaruoT. p53 Tumor suppressor protein content in human uterine leiomyomas and its down-regulation by 17 beta-estradiol. J Clin Endocrinol Metab. 2002;87(8):3915–3920.
66.
Nierth-SimpsonENMartinMMChiangTC. Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation. Endocrinology. 2009;150(5):2436–2445.
67.
YuLSaileKSwartzCD. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol Med. 2008;14(5-6):264–275.
68.
LesslMKlotzbuecherMSchoenSRelesAStockemannKFuhrmannU. Comparative messenger ribonucleic acid analysis of immediate early genes and sex steroid receptors in human leiomyoma and healthy myometrium. J Clin Endocrinol Metab. 1997;82(8):2596–2600.
69.
CrabtreeJSJelinskySAHarrisHA. Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway. Cancer Res. 2009;69(15):6171–6178.
70.
KarraLShushanABen-MeirA. Changes related to phosphatidylinositol 3-kinase/Akt signaling in leiomyomas: possible involvement of glycogen synthase kinase 3alpha and cyclin D2 in the pathophysiology. Fertil Steril. 2010;93(8):2646–2651.
71.
AsadaHYamagataYTaketaniT. Potential link between estrogen receptor-alpha gene hypomethylation and uterine fibroid formation. Mol Hum Reprod. 2008;14(9):539–545.
72.
MaekawaRSatoSYamagataY. Genome-wide DNA methylation analysis reveals a potential mechanism for the pathogenesis and development of uterine leiomyomas. PLoS One. 2013;8(6):e66632.
73.
Chabbert-BuffetNEsberNBouchardP. Fibroid growth and medical options for treatment. Fertil Steril. 2014;102(3):630–639.
74.
Di LietoADe FalcoMPollioF. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig. 2005;12(2):123–128.
75.
WangYMatsuoHKurachiOMaruoT. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells. Eur J Endocrinol. 2002;146(3):447–456.
76.
CheginiNKornbergL. Gonadotropin releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma. J Soc Gynecol Investig. 2003;10(1):21–26.
77.
LethabyAEVollenhovenBJ. An evidence-based approach to hormonal therapies for premenopausal women with fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(2):307–331.
78.
KettelLMMurphyAAMoralesAJRivierJValeWYenSS. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril. 1993;60(4):642–646.
79.
Gonzalez-BarcenaDAlvarezRBOchoaEP. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod. 1997;12(9):2028–2035.
80.
IshikawaHFenkciVMarshEE. CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma. J Clin Endocrinol Metab. 2008;93(3):981–991.
81.
HummelCWGeiserAGBryantHU. A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats. J Med Chem. 2005;48(22):6772–6775.
82.
ParsanezhadMEAzmoonMAlborziS. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010;93(1):192–198.
83.
VarelasFKPapanicolaouANVavatsi-ChristakiNMakedosGAVlassisGD. The effect of anastrazole on symptomatic uterine leiomyomata. Obstet Gynecol. 2007;110(3):643–649.
ShozuMMurakamiKInoueM. Aromatase and leiomyoma of the uterus. Semin Reprod Med. 2004;22(1):51–60.
86.
LewisJSJordanVC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res. 2005;591(1-2):247–263.
87.
CuzickJSestakIBonanniB. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827–1834.
88.
RiggsBLHartmannLC. Selective estrogen-receptor modulators—mechanisms of action and application to clinical practice. N Engl J Med. 2003;348(7):618–629.
89.
MoroniRVieiraCFerrianiRCandido-Dos-ReisFBritoL. Pharmacological treatment of uterine fibroids. Ann Med Health Sci Res. 2014;4(suppl 3): S185–S192.
90.
ManselRGoyalANestourELMasini-EteveVO’ConnellK; Afimoxifene Breast Pain Research Group. A phase II trial of afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women. Breast Cancer Res Treat. 2007;106(3):389–397.
91.
OverkCRPengKWAsghodomRT. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene. Chem Med Chem. 2007;2(10):1520–1526.
92.
BiskobingDM. Update on bazedoxifene: a novel selective estrogen receptor modulator. Clin Interv Aging. 2007;2(3):299–303.
93.
OharaN. Selective estrogen receptor modulator and selective progesterone receptor modulator: therapeutic efficacy in the treatment of uterine leiomyoma. Clin Exp Obstet Gynecol. 2005;32(1):9–11.
94.
SadanOGinathSSoferD. The role of tamoxifen in the treatment of symptomatic uterine leiomyomata—a pilot study. Eur J Obstet Gynecol Reprod Biol. 2001;96(2):183–186.
95.
HuppertLC. Induction of ovulation with clomiphene citrate. Fertil Steril. 1979;31(1):1–8.
96.
PalombaSRussoTOrioFJr. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod. 2002;17(12):3213–3219.
97.
PalombaSZulloFOrioFJrLombardiG. Does raloxifene inhibit the growth of uterine fibroids?Fertil Steril. 2004;81(6):1719–1720; author reply 1720-1711.
98.
LiuJMatsuoHXuQChenWWangJMaruoT. Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro. Hum Reprod. 2007;22(5):1253–1259.
99.
PalombaSSammartinoADi CarloCAffinitoPZulloFNappiC. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril. 2001;76(1):38–43.
100.
PalombaSOrioFJrRussoT. Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women. Fertil Steril. 2005;84(1):154–161.
Al-HendyASalamaS. Gene therapy and uterine leiomyoma: a review. Hum Reprod Update. 2006;12(4):385–400.
103.
Al-HendyALeeEJWangHQCoplandJA. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol. 2004;191(5):1621–1631.
104.
SalamaSANasrABDubeyRKAl-HendyA. Estrogen metabolite 2-methoxyestradiol induces apoptosis and inhibits cell proliferation and collagen production in rat and human leiomyoma cells: a potential medicinal treatment for uterine fibroids. J Soc Gynecol Investig. 2006;13(8):542–550.
105.
SalamaSAKamelMWBottingS. Catechol-o-methyltransferase expression and 2-methoxyestradiol affect microtubule dynamics and modify steroid receptor signaling in leiomyoma cells. PLoS One. 2009;4(10): e7356.
